Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
1.
J Anesth Analg Crit Care ; 2(1): 4, 2022 Jan 24.
Artículo en Inglés | MEDLINE | ID: mdl-37386589

RESUMEN

The inodilator levosimendan, in clinical use for over two decades, has been the subject of extensive clinical and experimental evaluation in various clinical settings beyond its principal indication in the management of acutely decompensated chronic heart failure. Critical care and emergency medicine applications for levosimendan have included postoperative settings, septic shock, and cardiogenic shock. As the experience in these areas continues to expand, an international task force of experts from 15 countries (Austria, Belgium, China, Croatia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Spain, Sweden, Switzerland, and the USA) reviewed and appraised the latest additions to the database of levosimendan use in critical care, considering all the clinical studies, meta-analyses, and guidelines published from September 2019 to November 2021. Overall, the authors of this opinion paper give levosimendan a "should be considered" recommendation in critical care and emergency medicine settings, with different levels of evidence in postoperative settings, septic shock, weaning from mechanical ventilation, weaning from veno-arterial extracorporeal membrane oxygenation, cardiogenic shock, and Takotsubo syndrome, in all cases when an inodilator is needed to restore acute severely reduced left or right ventricular ejection fraction and overall haemodynamic balance, and also in the presence of renal dysfunction/failure.

2.
Int J Cardiol ; 184: 323-336, 2015 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-25734940

RESUMEN

In cardiac surgery, postoperative low cardiac output has been shown to correlate with increased rates of organ failure and mortality. Catecholamines have been the standard therapy for many years, although they carry substantial risk for adverse cardiac and systemic effects, and have been reported to be associated with increased mortality. On the other hand, the calcium sensitiser and potassium channel opener levosimendan has been shown to improve cardiac function with no imbalance in oxygen consumption, and to have protective effects in other organs. Numerous clinical trials have indicated favourable cardiac and non-cardiac effects of preoperative and perioperative administration of levosimendan. A panel of 27 experts from 18 countries has now reviewed the literature on the use of levosimendan in on-pump and off-pump coronary artery bypass grafting and in heart valve surgery. This panel discussed the published evidence in these various settings, and agreed to vote on a set of questions related to the cardioprotective effects of levosimendan when administered preoperatively, with the purpose of reaching a consensus on which patients could benefit from the preoperative use of levosimendan and in which kind of procedures, and at which doses and timing should levosimendan be administered. Here, we present a systematic review of the literature to report on the completed and ongoing studies on levosimendan, including the newly commenced LEVO-CTS phase III study (NCT02025621), and on the consensus reached on the recommendations proposed for the use of preoperative levosimendan.


Asunto(s)
Procedimientos Quirúrgicos Cardíacos/métodos , Hidrazonas/uso terapéutico , Atención Perioperativa/métodos , Cuidados Preoperatorios/métodos , Piridazinas/uso terapéutico , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Cardiotónicos/uso terapéutico , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/cirugía , Ensayos Clínicos como Asunto/métodos , Europa (Continente)/epidemiología , Humanos , Simendán
3.
Anaesthesist ; 63(12): 951-7, 2014 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-25501914

RESUMEN

Diastolic heart failure leads to an increase in perioperative morbidity and mortality. The prevalence of this disease is rising and multiple risk factors have already been identified. Besides higher age and female gender, arterial hypertension, diabetes mellitus and coronary artery disease in particular have to be considered. Clinical examination and laboratory analyses are important for preoperative evaluation; however, echocardiography plays the most important role in the diagnostics of diastolic heart failure. The transmitral flow profile can be used to differentiate the grades of diastolic dysfunction using the ratio between early passive ventricular filling (E) and late active filling due to atrial contraction (A). Data concerning the ideal anesthesia technique are for the most part lacking; however, the application of thoracic epidural anesthesia seems to be beneficial. A great deal of attention has to be paid to the intraoperative volume status of patients with diastolic dysfunction as hypovolemia and hypervolemia can both have detrimental effects. Arrhythmias and major changes in blood pressure put this special group of patients at additional risks.


Asunto(s)
Anestesia/métodos , Insuficiencia Cardíaca/terapia , Atención Perioperativa/métodos , Ecocardiografía Transesofágica , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/epidemiología , Hemodinámica , Humanos , Factores de Riesgo
4.
Hamostaseologie ; 34(1): 40-5, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24071994

RESUMEN

In patients pretreated with P2Y12 receptor inhibitors who need to undergo non-emergent cardiac or major non-cardiac surgery, current guidelines of the European Society of Cardiology recommend postponing surgery for at least five days after last intake of clopidogrel or ticagrelor, and for seven days after last intake of prasugrel, unless there is high risk of ischemic events. However, a fixed five to seven days preoperative waiting period may be challenged, in the presence of inter-individual variability in on-treatment platelet reactivity. Therefore, Society of Thoracic Surgeons guidelines suggest to base decisions about a surgical delay on platelet function although both, the optimal platelet function assay and a bleeding cutoff have not yet been defined by large scale multicenter trials. This review aims to provide an overview on current knowledge of P2Y12 receptor induced platelet inhibition and surgery related bleeding and the potential role of platelet function analysis to time surgery.


Asunto(s)
Pérdida de Sangre Quirúrgica/prevención & control , Inhibidores de Agregación Plaquetaria/administración & dosificación , Pruebas de Función Plaquetaria/métodos , Hemorragia Posoperatoria/inducido químicamente , Hemorragia Posoperatoria/prevención & control , Antagonistas del Receptor Purinérgico P2Y/administración & dosificación , Privación de Tratamiento , Quimioterapia Combinada/efectos adversos , Humanos , Inhibidores de Agregación Plaquetaria/efectos adversos , Antagonistas del Receptor Purinérgico P2Y/efectos adversos , Factores de Tiempo
5.
Anaesthesist ; 62(4): 293-5, 2013 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-23494023

RESUMEN

A 29-year-old primagravida developed severe chest pains during labor. An emergency caesarean section was performed as the symptoms persisted. Imaging diagnosis immediately after delivery revealed an acute proximal (type A) aortic dissection. The patient was transferred to the nearest cardiothoracic surgery centre and successful emergency surgical aortic repair was performed. The perioperative course of a type A aortic dissection during pregnancy and labor is complicated by time pressure, diagnostic restrictions until delivery and potentially fatal uterine bleeding during cardiopulmonary bypass and hypothermic cardiac arrest. This case report describes the diagnosis and the surgical, anesthesiological and gynecological management of this life-threatening peripartum complication.


Asunto(s)
Aneurisma de la Aorta/cirugía , Disección Aórtica/cirugía , Complicaciones Cardiovasculares del Embarazo/cirugía , Adulto , Anestesia , Disección Aórtica/diagnóstico por imagen , Aneurisma de la Aorta/diagnóstico por imagen , Cesárea , Ecocardiografía , Ecocardiografía Transesofágica , Electrocardiografía , Servicios Médicos de Urgencia , Femenino , Humanos , Periodo Periparto , Embarazo , Complicaciones Cardiovasculares del Embarazo/diagnóstico por imagen , Tomografía Computarizada por Rayos X
6.
Anaesthesist ; 59(5): 427-32, 2010 May.
Artículo en Alemán | MEDLINE | ID: mdl-20383477

RESUMEN

The timely administration of endocarditis prophylaxis means an additional stress situation for many children and their parents in an already stressful preoperative period. In addition it causes an increased organizational effort most of all in the day care department. Over many decades the use of prophylactic antibiotics to prevent infective endocarditis was recommended in patients with underlying cardiac conditions undergoing medical procedures which could lead to bacteraemia. However, transient bacteraemia occurs commonly during routine daily activities such as cleaning teeth or chewing. Most cases of endocarditis are not related to a medical procedure. There are currently no randomized and carefully controlled human trials to definitely prove the effectiveness and efficiency of endocarditis prophylaxis. Therefore, the new guidelines recommend the use of antibiotic prophylaxis only for cardiac conditions associated with the highest risk of adverse outcome from endocarditis. In paediatric surgery and paediatric anaesthesiology this applies mainly to patients with congenital heart disease. The implementation of the new guidelines in the Department of Paediatric Surgery at the Medical University Graz is illustrated in the following article.


Asunto(s)
Profilaxis Antibiótica , Endocarditis Bacteriana/prevención & control , Complicaciones Posoperatorias/prevención & control , Adolescente , Bacteriemia/prevención & control , Niño , Adhesión a Directriz , Guías como Asunto , Cardiopatías Congénitas/complicaciones , Humanos , Medición de Riesgo
9.
Acta Anaesthesiol Scand ; 51(1): 68-73, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17229230

RESUMEN

BACKGROUND: Inhalation of hyperbaric oxygen (HBO) has been reported to decrease arterial oxygen tension (PaO(2)) in the early period after exposure. The current investigation aimed at evaluating whether and to what extent arterial blood gases were affected in mechanically ventilated intensive care patients within 6 h after HBO treatment. METHODS: Arterial blood gases were measured in 11 ventilated subjects [nine males, two females, synchronized intermittent mandatory ventilation (SIMV) mode] undergoing HBO therapy for necrotizing soft tissue infection (seven patients), burn injury (two patients), crush injury (one patient) and major abdominal surgery (one patient). Blood gases were obtained with the patients in the supine position under continuous analgesia and sedation before the hyperbaric session (baseline), during isopression, after decompression, after each transport, and 1, 2, 3 and 6 h after exposure. Heart rates and blood pressures were recorded. Intensive care unit (ICU) ventilator settings remained unchanged. Transport and chamber ventilator settings were adjusted to baseline with maintenance of tidal volumes and positive end-expiratory pressure (PEEP) levels. The hyperbaric protocol consisted of 222.9 kPa (2.2 absolute atmospheres) and a 50-min isopression phase. The paired Wilcoxon's test was used. RESULTS: Major findings (median values, 25%/75% quartiles) as per cent change of baseline: PaO(2) values decreased by 19.7% (7.0/31.7, P < 0.01) after 1 h and were elevated over baseline by 9.3% (1.5/13.7, P < 0.05) after 3 h. SaO(2), alveolar-arterial oxygen tension difference and PaO(2)/FiO(2) ratio behaved concomitantly. Acid-base status and carbon dioxide tension were unaffected. CONCLUSION: Arterial oxygen tension declines transiently after HBO and subsequently improves over baseline in intensive care patients on volume-controlled mechanical ventilation. The effectiveness of other ventilation modes or a standardized recruitment manoeuvre has yet to be evaluated.


Asunto(s)
Oxigenoterapia Hiperbárica , Oxígeno/sangre , Equilibrio Ácido-Base , Anciano , Dióxido de Carbono/sangre , Cuidados Críticos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Respiración Artificial
10.
Acta Anaesthesiol Scand ; 50(6): 768-70, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16987377

RESUMEN

BACKGROUND: Administration of high doses of prostaglandins is a frequently performed and effective method for the treatment of atonic uterine haemorrhage in order to increase uterine muscle tone. Rarely, however, these drugs may cause life-threatening complications including bronchospasm, acute pulmonary oedema and myocardial infarction caused by coronary spasms. METHODS: We discuss the management of a patient suffering post-partum atonic uterine bleeding, catecholamine-resistant cardiac arrest and fulminant pulmonary failure due to deleterious side-effects of treatment with prostaglandins. RESULTS: During therapy resistant cardiopulmonary resuscitation, the addition of levosimendan to standard medications resulted in a prompt stabilization of haemodynamics. Subsequent treatment of pulmonary failure was successfully managed with ECMO. CONCLUSION: Although levosimendan is not approved for pharmacological treatment of cardiopulmonary arrest, the beneficial effects in this patient suggest an important role of calcium sensitization and vasodilation during prostaglandin-induced cardiac arrest.


Asunto(s)
Cardiotónicos/uso terapéutico , Oxigenación por Membrana Extracorpórea , Paro Cardíaco/inducido químicamente , Paro Cardíaco/tratamiento farmacológico , Hidrazonas/uso terapéutico , Prostaglandinas/efectos adversos , Piridazinas/uso terapéutico , Adulto , Catecolaminas/uso terapéutico , Cesárea , Resistencia a Medicamentos , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/tratamiento farmacológico , Hemorragia Posparto/tratamiento farmacológico , Embarazo , Simendán , Resultado del Tratamiento , Enfermedades Uterinas/tratamiento farmacológico
11.
J Thromb Haemost ; 2(1): 147-53, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14717978

RESUMEN

Maximum amplitude (MA) in thrombelastography (TEG) consists of a plasmatic and a platelet component. To assess the magnitude of the plasmatic component, pharmacological approaches have been proposed to eliminate the platelet component. We evaluated the individual and combined effects of abciximab and cytochalasin D on the MA of TEG. Whole blood, platelet-rich plasma (PRP) and homologous platelet-poor plasma (PPP) from 20 healthy volunteers were spiked with abciximab or cytochalasin D or a combination of both and TEGs performed. Abciximab and cytochalasin D decreased MA in all samples. MA of whole blood (18.6 +/- 3.1 mm) and PRP (33.7 +/- 3.5 mm) spiked with abciximab or cytochalasin D alone (15.0 +/- 2.9 mm and 25.0 +/- 4.0 mm) were significantly higher when compared with abciximab and cytochalasin D combined (10.4 +/- 3.0 and 20.2 +/- 3.5 mm). While MA of PRP and homologous PPP were significantly (P < 0.001) different after individual administration of abciximab and cytochalasin D, combination of both abolished this difference (20.2 +/- 3.5 mm and 20.4 +/- 3.7 mm, P = 0.372). In whole blood of critically ill patients or patients undergoing major surgery there was also a significant difference of MA between abciximab alone and in combination with cytochalasin D (16.5 +/- 11.3 mm and 11.3 +/- 7.7 mm, P < 0.001). This indicates that in contrast to individual administration of abciximab or cytochalasin D, a combination of both compounds eliminates the platelet-specific effect on MA of TEG tracings.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Coagulación Sanguínea/efectos de los fármacos , Citocalasina D/farmacología , Fragmentos Fab de Inmunoglobulinas/farmacología , Abciximab , Adulto , Anciano , Anticuerpos Monoclonales/administración & dosificación , Plaquetas/efectos de los fármacos , Citocalasina D/administración & dosificación , Citoesqueleto/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Femenino , Humanos , Fragmentos Fab de Inmunoglobulinas/administración & dosificación , Técnicas In Vitro , Masculino , Persona de Mediana Edad , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Tromboelastografía
12.
Biol Bull ; 201(3): 348-59, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11751247

RESUMEN

Corals of the Montastraea annularis complex host several different dinoflagellates in the genus Symbiodinium. Here we address two questions arising from our previous studies of these associations on an offshore reef. First, do the same taxa and patterns of association (Symbiodinium A and B found in higher irradiance habitats than Symbiodinium C) occur on an inshore reef? Second, does M. franksi at the limits of its depth range host only Symbiodinium C, as it does at intermediate depths? In both surveys, a new Symbiodinium taxon and different patterns of distribution (assayed by analyses of small ribosomal subunit RNA genes [srDNA]) were observed. Inshore, a taxon we name Symbiodinium E predominated in higher irradiance habitats in M. franksi and its two sibling species; the only other zooxanthella observed was Symbiodinium C. Offshore, M. franksi mainly hosted Symbiodinium C, but hosted Symbiodinium A, B, C, and E in shallow water and Symbiodinium E and C in very deep water. Symbiodinium E may be stress-tolerant. Observed srDNA heterogeneity within samples of Symbiodinium B, C, and E is interpreted as variation across copies within this multigene family. Experimental bleaching of Symbiodinium C supported this interpretation. Thus sequences from natural samples should be interpreted cautiously.


Asunto(s)
Cnidarios/parasitología , Dinoflagelados/crecimiento & desarrollo , Filogenia , Animales , Secuencia de Bases , Análisis por Conglomerados , ADN Protozoario/química , ADN Protozoario/genética , ADN Protozoario/aislamiento & purificación , ADN Ribosómico/química , ADN Ribosómico/genética , ADN Ribosómico/aislamiento & purificación , Dinoflagelados/química , Dinoflagelados/genética , Datos de Secuencia Molecular , Panamá , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de Restricción , Simbiosis
13.
Biol Bull ; 201(3): 360-73, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11751248

RESUMEN

Caribbean corals of the Montastraea annularis species complex associate with four taxa of symbiotic dinoflagellates (zooxanthellae; genus Symbiodinium) in ecologically predictable patterns. To investigate the resilience of these host-zooxanthella associations, we conducted field experiments in which we experimentally reduced the numbers of zooxanthellae (by transplanting to shallow water or by shading) and then allowed treated corals to recover. When depletion was not extreme, recovering corals generally contained the same types of zooxanthellae as they did prior to treatment. After severe depletion, however, recovering corals were always repopulated by zooxanthellae atypical for their habitat (and in some cases atypical for the coral species). These unusual zooxanthellar associations were often (but not always) established in experimentally bleached tissues even when adjacent tissues were untreated. Atypical zooxanthellae were also observed in bleached tissues of unmanipulated Montastraea with yellow-blotch disease. In colonies where unusual associations were established, the original taxa of zooxanthellae were not detected even 9 months after the end of treatment. These observations suggest that zooxanthellae in Montastraea range from fugitive opportunists and stress-tolerant generalists (Symbiodinium A and E) to narrowly adapted specialists (Symbiodinium B and C), and may undergo succession.


Asunto(s)
Cnidarios/parasitología , Dinoflagelados/crecimiento & desarrollo , Animales , Secuencia de Bases , ADN Protozoario/química , ADN Protozoario/genética , ADN Protozoario/aislamiento & purificación , ADN Ribosómico/química , ADN Ribosómico/genética , ADN Ribosómico/aislamiento & purificación , Dinoflagelados/química , Dinoflagelados/genética , Luz , Datos de Secuencia Molecular , Panamá , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de Restricción , Simbiosis
14.
Am J Physiol Heart Circ Physiol ; 281(5): H2097-104, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11668071

RESUMEN

We tested the hypothesis that hyperglycemia alters retrograde coronary collateral blood flow by a nitric oxide-mediated mechanism in a canine Ameriod constrictor model of enhanced collateral development. Administration of 15% dextrose to increase blood glucose concentration to 400 or 600 mg/dl decreased retrograde blood flow through the left anterior descending coronary artery to 78 +/- 9 and 82 +/- 8% of baseline values, respectively. In contrast, saline or L-arginine (400 mg x kg(-1) x h(-1)) had no effect on retrograde flow. Coronary hypoperfusion and 1 h of reperfusion decreased retrograde blood flow similarly in saline- or L-arginine-treated dogs (76 +/- 11 and 89 +/- 4% of baseline, respectively), but these decreases were more pronounced in hyperglycemic dogs (47 +/- 10%). L-arginine prevented decreases in retrograde coronary collateral blood flow during hyperglycemia (100 +/- 5 and 95 +/- 6% of baseline at blood glucose concentrations of 400 and 600 mg/dl, respectively) and after coronary hypoperfusion and reperfusion (84 +/- 14%). The results suggest that hyperglycemia decreases retrograde coronary collateral blood flow by adversely affecting nitric oxide availability.


Asunto(s)
Circulación Colateral/fisiología , Circulación Coronaria/fisiología , Hiperglucemia/fisiopatología , Óxido Nítrico/metabolismo , Animales , Arginina/farmacología , Circulación Colateral/efectos de los fármacos , Circulación Coronaria/efectos de los fármacos , Modelos Animales de Enfermedad , Perros , Hiperglucemia/metabolismo , Microcirculación/efectos de los fármacos , Microcirculación/fisiología , Isquemia Miocárdica/metabolismo , Isquemia Miocárdica/fisiopatología , Daño por Reperfusión Miocárdica/metabolismo , Daño por Reperfusión Miocárdica/fisiopatología
15.
Am J Physiol Heart Circ Physiol ; 280(4): H1744-50, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11247788

RESUMEN

Hyperglycemia is an important predictor of cardiovascular mortality in patients with diabetes. We investigated the hypothesis that diabetes or acute hyperglycemia attenuates the reduction of myocardial infarct size produced by activation of mitochondrial ATP-regulated potassium (K(ATP)) channels. Acutely instrumented barbiturate-anesthetized dogs were subjected to a 60-min period of coronary artery occlusion and 3 h of reperfusion. Myocardial infarct size (triphenyltetrazolium chloride staining) was 25 +/- 1, 28 +/- 3, and 25 +/- 1% of the area at risk (AAR) for infarction in control, diabetic (3 wk after streptozotocin-alloxan), and hyperglycemic (15% intravenous dextrose) dogs, respectively. Diazoxide (2.5 mg/kg iv) significantly decreased infarct size (10 +/- 1% of AAR, P < 0.05) but did not produce protection in the presence of diabetes (28 +/- 5%) or moderate hyperglycemia (blood glucose 310 +/- 10 mg/dl; 23 +/- 2%). The dose of diazoxide and the degree of hyperglycemia were interactive. Profound (blood glucose 574 +/- 23 mg/dl) but not moderate hyperglycemia blocked the effects of high-dose (5.0 mg/kg) diazoxide [26 +/- 3, 15 +/- 3 (P < 0.05), and 11 +/- 2% (P < 0.05), respectively]. There were no differences in systemic hemodynamics, AAR, or coronary collateral blood flow (by radioactive microspheres) between groups. The results indicate that diabetes or hyperglycemia impairs activation of mitochondrial K(ATP) channels.


Asunto(s)
Diabetes Mellitus Experimental/fisiopatología , Hemodinámica/fisiología , Hiperglucemia/fisiopatología , Proteínas de la Membrana/fisiología , Infarto del Miocardio/fisiopatología , Análisis de Varianza , Animales , Glucemia/metabolismo , Presión Sanguínea , Dióxido de Carbono/sangre , Circulación Coronaria/efectos de los fármacos , Circulación Coronaria/fisiología , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/fisiopatología , Diazóxido/farmacología , Perros , Endocardio/efectos de los fármacos , Endocardio/fisiopatología , Frecuencia Cardíaca , Hemodinámica/efectos de los fármacos , Humanos , Mitocondrias/fisiología , Infarto del Miocardio/patología , Oxígeno/sangre , Canales de Potasio , Vasodilatadores/farmacología , Función Ventricular Izquierda
16.
Anesth Analg ; 92(2): 299-305, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11159220

RESUMEN

Chronic, intermittent exposure to small amounts of ethanol reduces myocardial infarct size in vivo. We tested the hypothesis that acute administration of ethanol enhances the functional recovery of stunned myocardium and that adenosine triphosphate-dependent potassium (K(ATP)) channels mediate this beneficial effect. Barbiturate-anesthetized dogs were instrumented for measurement of aortic and left ventricular pressure, +dP/dt(max), and subendocardial segment shortening (%SS) and were subjected to five 5-min periods of coronary artery occlusion, each separated by 5 min of reperfusion followed by a 3-h final reperfusion. In four groups (n = 7 each), dogs received 0.9% saline or ethanol (0.25, 0.5, or 1.0 g/kg over 30 min) in a random manner before occlusions and reperfusions. In other groups (n = 7 each), dogs received the K(ATP) channel antagonist glyburide (0.3 mg/kg, IV) 30 min before saline or ethanol (0.25 g/kg) was administered. Dogs receiving saline or glyburide alone demonstrated poor recovery of contractile function during reperfusion (%SS = 0.9% +/- 2.0% and 1.6% +/- 1.2% at 3 h, respectively). Recovery of %SS was enhanced in dogs receiving the 0.25- and 0.5-g/kg doses of ethanol (10.0% +/- 1.8% and 8.6% +/- 2.2% at 3 h, respectively) independent of alterations in hemodynamics or coronary collateral blood flow (radioactive microspheres). Glyburide did not affect improvement of recovery of stunned myocardium produced by ethanol (11.8% +/- 2.2% at 3 h). The results indicate that ethanol enhances the functional recovery of stunned myocardium independent of K(ATP) channels in vivo.


Asunto(s)
Adenosina Trifosfato/farmacología , Etanol/farmacología , Aturdimiento Miocárdico/fisiopatología , Canales de Potasio/fisiología , Animales , Perros , Etanol/sangre , Etanol/uso terapéutico , Gliburida/farmacología , Aturdimiento Miocárdico/tratamiento farmacológico
17.
Am J Physiol Heart Circ Physiol ; 279(5): H2574-9, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11045996

RESUMEN

Chronic ingestion of low doses of ethanol protects the myocardium from ischemic injury by activating adenosine receptors and protein kinase C. We tested the hypothesis that ATP-dependent potassium (K(ATP)) channels mediate these beneficial effects. Dogs were fed with ethanol (1.5 g/kg) or water mixed with dry food twice per day for 12 wk. After they were acutely instrumented for measurement of hemodynamics, dogs received saline (vehicle) or glyburide (0.1 mg/kg iv) and were subjected to 60 min of coronary artery occlusion followed by 3 h of reperfusion. Infarct size (through triphenyltetrazolium chloride staining) was significantly (P < 0.05) reduced to 14 +/- 1% of the left ventricular area at risk in ethanol-pretreated dogs compared with controls (25 +/- 2%). Glyburide alone did not affect infarct size (25 +/- 3%) but abolished the protective effects of ethanol pretreatment (28 +/- 3%). No differences in hemodynamics or coronary collateral blood flow (through radioactive microspheres) were observed among groups. The results indicate that K(ATP) channels mediate the protective effects of chronic consumption of ethanol.


Asunto(s)
Adenosina Trifosfato/metabolismo , Etanol/administración & dosificación , Corazón/efectos de los fármacos , Infarto del Miocardio/metabolismo , Canales de Potasio/metabolismo , Administración Oral , Animales , Circulación Colateral/efectos de los fármacos , Circulación Colateral/fisiología , Circulación Coronaria/efectos de los fármacos , Circulación Coronaria/fisiología , Perros , Esquema de Medicación , Gliburida/farmacología , Corazón/fisiología , Hemodinámica/efectos de los fármacos , Infarto del Miocardio/patología , Infarto del Miocardio/prevención & control , Proteína Quinasa C/metabolismo , Receptores Purinérgicos P1/metabolismo
18.
Crit Care Med ; 28(8): 2893-7, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10966267

RESUMEN

OBJECTIVE: Catecholamines are frequently used in critically ill patients to restore stable hemodynamics and to improve organ perfusion. One effect of short-term or long-term administration of catecholamines may be inhibition of propulsive motility in the intestine. We therefore analyzed the effect of dopexamine, dobutamine, and dopamine on ileal peristalsis and compared their action with that of epinephrine and norepinephrine, which have long been known to suppress intestinal peristalsis. DESIGN: In vitro study on excised guinea pig ileum segments. SETTING: Laboratory for experimental studies at the University. SUBJECTS: Isolated guinea pig ileum. INTERVENTIONS: Segments of ileum excised from guinea pigs were mounted in a tissue bath in Krebs-Henseleit solution and bubbled with 95% oxygen/5% CO2. Luminal perfusion with the same solution was performed at a rate of 0.35 mL/min. The bath temperature was kept at 36.5 degrees C. Peristalsis was recorded via changes in the intraluminal pressure. The drugs under investigation (dopamine, epinephrine, norepinephrine, dobutamine, and dopexamine) were added to the tissue bath. MEASUREMENTS AND MAIN RESULTS: Low concentrations of each catecholamine, except epinephrine, caused a decrease in the pressure threshold, which reflects a stimulatory effect on peristalsis. Higher catecholamine concentrations caused a concentration-related increase in the threshold, cumulating in a complete block of peristalsis. The rank order of inhibitory potency was epinephrine > norepinephrine > dopamine > dobutamine approximately dopexamine. Dobutamine and dopexamine were about 500-fold less active than epinephrine in suppressing peristalsis. CONCLUSIONS: This study shows that dobutamine and dopexamine have the least potential to block propulsive motility in the intestine, whereas epinephrine demonstrates the most adverse inhibitory effect. Because at low concentrations dobutamine and dopexamine even stimulate peristalsis, these drugs appear to be superior compared with other catecholamines with regard to their direct effects on intestinal motility.


Asunto(s)
Agonistas Adrenérgicos beta/farmacología , Dobutamina/farmacología , Dopamina/análogos & derivados , Epinefrina/farmacología , Norepinefrina/farmacología , Peristaltismo/efectos de los fármacos , Animales , Dopamina/farmacología , Cobayas , Técnicas In Vitro
19.
Anesthesiology ; 92(6): 1731-9, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10839925

RESUMEN

BACKGROUND: Volatile anesthetic-induced preconditioning is mediated by adenosine triphosphate-dependent potassium (KATP) channels; however, the subcellular location of these channels is unknown. The authors tested the hypothesis that desflurane reduces experimental myocardial infarct size by activation of specific sarcolemmal and mitochondrial KATP channels. METHODS: Barbiturate-anesthetized dogs (n = 88) were acutely instrumented for measurement of aortic and left ventricular pressures. All dogs were subjected to a 60-min left anterior descending coronary artery occlusion followed by 3-h reperfusion. In four separate groups, dogs received vehicle (0.9% saline) or the nonselective KATP channel antagonist glyburide (0.1 mg/kg intravenously) in the presence or absence of 1 minimum alveolar concentration desflurane. In four additional groups, dogs received 45-min intracoronary infusions of the selective sarcolemmal (HMR 1098; 1 microg. kg-1. min-1) or mitochondrial (5-hydroxydecanoate [5-HD]; 150 microg. kg-1. min-1) KATP channel antagonists in the presence or absence of desflurane. Myocardial perfusion and infarct size were measured with radioactive microspheres and triphenyltetrazolium staining, respectively. RESULTS: Desflurane significantly (P < 0.05) decreased infarct size to 10 +/- 2% (mean +/- SEM) of the area at risk as compared with control experiments (25 +/- 3% of area at risk). This beneficial effect of desflurane was abolished by glyburide (25 +/- 2% of area at risk). Glyburide (24 +/- 2%), HMR 1098 (21 +/- 4%), and 5-HD (24 +/- 2% of area at risk) alone had no effects on myocardial infarct size. HMR 1098 and 5-HD abolished the protective effects of desflurane (19 +/- 3% and 22 +/- 2% of area at risk, respectively). CONCLUSION: Desflurane reduces myocardial infarct size in vivo, and the results further suggest that both sarcolemmal and mitochondrial KATP channels could be involved.


Asunto(s)
Adenosina Trifosfato/fisiología , Anestésicos por Inhalación/farmacología , Isoflurano/análogos & derivados , Mitocondrias/metabolismo , Canales de Potasio/metabolismo , Sarcolema/metabolismo , Adenosina Trifosfato/metabolismo , Anestésicos por Inhalación/antagonistas & inhibidores , Animales , Benzamidas/farmacología , Ácidos Decanoicos/farmacología , Desflurano , Perros , Gliburida/farmacología , Hemodinámica/efectos de los fármacos , Hidroxiácidos/farmacología , Hipoglucemiantes/farmacología , Precondicionamiento Isquémico Miocárdico , Isoflurano/antagonistas & inhibidores , Isoflurano/farmacología , Infarto del Miocardio/patología , Infarto del Miocardio/prevención & control , Miocardio/patología , Bloqueadores de los Canales de Potasio , Canales de Potasio/agonistas , Flujo Sanguíneo Regional
20.
Anesthesiology ; 92(5): 1400-7, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10781287

RESUMEN

BACKGROUND: Isoflurane-induced myocardial protection during ischemia is mediated by adenosine triphosphate-regulated potassium (KATP) channels; however, the intracellular signal transduction cascade responsible for this process has been incompletely evaluated. The authors tested the hypothesis that isoflurane reduces myocardial infarct size through a Gi protein-mediated process. METHODS: Forty-eight hours after pretreatment with vehicle (0.9% saline) or the Gi protein inhibitor pertussis toxin (10 microg/kg intravenously), barbiturate-anesthetized dogs (n = 43) were instrumented for measurement of aortic and left ventricular pressures and maximum rate of increase of left ventricular pressure. All dogs were subjected to a 60-min left anterior descending coronary artery occlusion followed by 3-h reperfusion. In four separate groups, vehicle- or pertussis toxin-pretreated dogs were studied with or without administration of 1 minimum alveolar concentration isoflurane. In two additional groups, dogs received the direct KATP channel agonist nicorandil (100 microg/kg bolus and 10 microg x kg-1 x min-1 intravenous infusion) in the presence or absence of pertussis toxin pretreatment. Myocardial perfusion and infarct size were measured with radioactive microspheres and triphenyltetrazolium staining, respectively. RESULTS: Isoflurane significantly (P < 0.05) decreased infarct size to 7 +/- 2% of the area at risk compared with control experiments (26 +/- 2%). Pertussis toxin pretreatment alone had no effects on myocardial infarct size (31 +/- 4%) but blocked the beneficial effects of isoflurane (21 +/- 3%). Nicorandil decreased infarct size (11 +/- 2%), but, in contrast to isoflurane, this effect was independent of pertussis toxin pretreatment (11 +/- 1%). CONCLUSION: Isoflurane reduces myocardial infarct size by a Gi protein-mediated mechanism in vivo.


Asunto(s)
Anestésicos por Inhalación/uso terapéutico , Proteínas de Unión al GTP/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Precondicionamiento Isquémico Miocárdico/métodos , Isoflurano/uso terapéutico , Infarto del Miocardio/prevención & control , Toxina del Pertussis , Factores de Virulencia de Bordetella/farmacología , Animales , Perros , Proteínas de Unión al GTP/metabolismo , Infarto del Miocardio/metabolismo , Nicorandil/farmacología , Canales de Potasio/efectos de los fármacos , Vasodilatadores/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...